OpenAI Sora leak: What it was and what it wasn’t.
Parkinson's Disease Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | AbbVie, Pfizer, Novartis, F. Roche, Kissei Pharma, AstraZeneca, Prevail Therapeutics, Amneal Pharma 11-21-2024 08:50 PM CET | Health & Medicine Press release from: DelveIinsight Business Research (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Parkinson's Disease pipeline constitutes 140+ key companies continuously working towards developing 150+ Parkinson's Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Parkinson's Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Parkinson's Disease Market. The Parkinson's Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Some of the key takeaways from the Parkinson's Disease Pipeline Report: https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr •Companies across the globe are diligently working toward developing novel Parkinson's Disease treatment therapies with a considerable amount of success over the years. •Parkinson's Disease companies working in the treatment market are FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd., Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others, are developing therapies for the Parkinson's Disease treatment •Emerging Parkinson's Disease therapies in the different phases of clinical trials are- KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others are expected to have a significant impact on the Parkinson's Disease market in the coming years. •In October 2024, Adaptive Research, a clinical trial site organization focused on making clinical trials more accessible, announced its involvement in a pioneering decentralized study for Parkinson's Disease sponsored by PhotoPharmics Inc. The California Movement Disorders Center, part of Adaptive Research's network, will be a site for PhotoPharmics' LIGHT-PD trial, which aims to evaluate the effectiveness of Celeste® Specialized Phototherapy in treating Parkinson's symptoms. •In September 2024, AbbVie's recently acquired Parkinson's disease treatment, tavapadon, demonstrated a significant reduction in disease burden in a Phase III trial. The TEMPO-1 trial (NCT04201093) assessed two daily doses of tavapadon (5mg and 15mg) and successfully met its primary endpoint. Both dosage groups outperformed the placebo in reducing disease burden at week 26, as evaluated by a combined score from the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). •In December 2023, Gain Therapeutics, a biotechnology company situated in the United States, has released preclinical findings showcasing the promise of small molecule allosteric regulators in addressing beta-galactosidase-1 (GLB1)-related lysosomal storage disorders, including GM1 gangliosidosis. •In December 2023, Vanqua Bio disclosed plans to commence clinical trials in the first quarter of 2024, evaluating the investigational drug VQ-101 as a potential treatment for Parkinson's disease linked to GBA1 mutations. Parkinson's Disease Overview Parkinson's disease is a progressive nervous system disorder that affects movement. It develops when there is a gradual loss of certain nerve cells in the brain that produce dopamine, a chemical messenger responsible for smooth and coordinated muscle movements. As dopamine levels decrease, individuals with Parkinson's disease experience difficulties with movement control. Get a Free Sample PDF Report to know more about Parkinson's Disease Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Emerging Parkinson's Disease Drugs Under Different Phases of Clinical Development Include: •KM-819: FAScinate Therapeutics •Prasinezumab: Hoffmann-La Roche •P2B001: Pharma Two B Ltd. •NPT1220-478: Neuropore Therapies, Inc. •Dapansutrile: Olatec Therapeutics •UCB7853: UCB Biopharma •UB-312: Vaxxinity •Emrusolmin: Modag •PT320: Peptron •KDT-3594: Kissei Pharmaceutical •Tavapadon: Cerevel Therapeutics Parkinson's Disease Route of Administration Parkinson's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as •Inhalation •Inhalation/Intravenous/Oral •Intranasal •Intravenous •Intravenous/ Subcutaneous •NA •Oral •Oral/intranasal/subcutaneous •Parenteral •Subcutaneous Parkinson's Disease Molecule Type Parkinson's Disease Products have been categorized under various Molecule types, such as •Antibody •Antisense oligonucleotides •Immunotherapy •Monoclonal antibody •Peptides •Protein •Recombinant protein •Small molecule •Stem Cell •Vaccine Parkinson's Disease Pipeline Therapeutics Assessment •Parkinson's Disease Assessment by Product Type •Parkinson's Disease By Stage and Product Type •Parkinson's Disease Assessment by Route of Administration •Parkinson's Disease By Stage and Route of Administration •Parkinson's Disease Assessment by Molecule Type •Parkinson's Disease by Stage and Molecule Type DelveInsight's Parkinson's Disease Report covers around 150+ products under different phases of clinical development like •Late-stage products (Phase III) •Mid-stage products (Phase II) •Early-stage product (Phase I) •Pre-clinical and Discovery stage candidates •Discontinued & Inactive candidates •Route of Administration Further Parkinson's Disease product details are provided in the report. Download the Parkinson's Disease pipeline report to learn more about the emerging Parkinson's Disease therapies https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key companies in the Parkinson's Disease Therapeutics Market include: Key companies developing therapies for Parkinson's Disease are - Pfizer Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Kissei Pharmaceutical Co., Ltd., AstraZeneca, Prevail Therapeutics, Amneal Pharmaceuticals LLC, AbbVie Inc., Viatris, Boehringer Ingelheim International GmbH, GSK plc, ABL bio, Teva Pharmaceuticals Industries Ltd, Newron Pharmaceuticals SPA, and others. Parkinson's Disease Pipeline Analysis: The Parkinson's Disease pipeline report provides insights into •The report provides detailed insights about companies that are developing therapies for the treatment of Parkinson's Disease with aggregate therapies developed by each company for the same. •It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson's Disease Treatment. •Parkinson's Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. •Parkinson's Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. •Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Parkinson's Disease market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Parkinson's Disease drugs and therapies https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Parkinson's Disease Pipeline Market Drivers •Increasing prevalence of Parkinson's Disease patients, robust clinical-stage pipeline are some of the important factors that are fueling the Parkinson's Disease Market. Parkinson's Disease Pipeline Market Barriers •However, lack of awareness and delayed diagnosis, side effects associated with Parkinson's disease treatment drugs and other factors are creating obstacles in the Parkinson's Disease Market growth. Scope of Parkinson's Disease Pipeline Drug Insight •Coverage: Global •Key Parkinson's Disease Companies: FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd., Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others •Key Parkinson's Disease Therapies: KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others •Parkinson's Disease Therapeutic Assessment: Parkinson's Disease current marketed and Parkinson's Disease emerging therapies •Parkinson's Disease Market Dynamics: Parkinson's Disease market drivers and Parkinson's Disease market barriers Request for Sample PDF Report for Parkinson's Disease Pipeline Assessment and clinical trials https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Table of Contents 1. Parkinson's Disease Report Introduction 2. Parkinson's Disease Executive Summary 3. Parkinson's Disease Overview 4. Parkinson's Disease- Analytical Perspective In-depth Commercial Assessment 5. Parkinson's Disease Pipeline Therapeutics 6. Parkinson's Disease Late Stage Products (Phase II/III) 7. Parkinson's Disease Mid Stage Products (Phase II) 8. Parkinson's Disease Early Stage Products (Phase I) 9. Parkinson's Disease Preclinical Stage Products 10. Parkinson's Disease Therapeutics Assessment 11. Parkinson's Disease Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Parkinson's Disease Key Companies 14. Parkinson's Disease Key Products 15. Parkinson's Disease Unmet Needs 16 . Parkinson's Disease Market Drivers and Barriers 17. Parkinson's Disease Future Perspectives and Conclusion 18. Parkinson's Disease Analyst Views 19. Appendix 20. About DelveInsight Latest Reports: •Arteriovenous Malformations Market: https://www.delveinsight.com/report-store/vascular-malformations-market •Mammography Devices Market: https://www.delveinsight.com/report-store/mammography-devices-market •Global Kinase Inhibitor Market: https://www.delveinsight.com/report-store/global-kinase-inhibitor-in-autoimmune-diseases-market-insight •Nerve Repair And Regeneration Devices- Market Insights: https://www.delveinsight.com/report-store/nerve-repair-and-regeneration-market •Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market •Diabetic Wound Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Contact Us: Gaurav Bora gbora@delveinsight.com +91-9650213330 Healthcare Consulting https://www.delveinsight.com/consulting-services Contact Us: Gaurav Bora gbora@delveinsight.com +14699457679 Healthcare Consulting https://www.delveinsight.com/consulting-services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. This release was published on openPR.
Srinagar, Nov 27: Veteran journalist and noted author, M L Kak, breathed his last on Wednesday morning in Gurugram after a prolonged illness. He was 85. Originally from Naidyar, Rainawari, in Kashmir, he lived first in Jammu and then in Gurugram for the last many years. He started his career as a journalist in The Tribune newspaper after receiving a postgraduate degree in English literature from the University of Kashmir (KU) and a Diploma in Journalism from Punjab University, Chandigarh. As The Tribune’s correspondent, he worked in Haryana, Himachal Pradesh, and J&K. When the Emergency was imposed in June 1975, he was amongst the top journalists and political leaders who were arrested and detained in Hissar Jail, after a showdown with the then Chief Minister of Haryana, Bansi Lal. After spending about 10 days in Hissar Jail, he was transferred to Central Jail Srinagar on the intervention of the then Chief Minister of J&K, Sheikh Muhammad Abdullah. The then Prime Minister of India, Indira Gandhi, went on record, describing his arrest as a “sheer misuse of Emergency powers” and ordered his immediate release. Kak was ultimately released from Central Jail, Srinagar, after spending another 60 days there. Kak authored many books: ‘Jailed without Crime: Untold Story of Emergency’, ‘Waves in Kashmir: History of Kashmir and Political Developments’, ‘Away From Homeland: Plight of Kashmiri Pandits Post Migration and Their Aspirations’ and ‘Behind The Veil’, a Collection of write ups published in a local English daily in Jammu about the issues related to J&K and Pakistan.International Workplace Group (IWG), the world’s largest provider of hybrid working solutions, has announced the opening of a new flexible workspace in Cairo. This new location, marking IWG’s 17th in Egypt, comes at a time when demand for hybrid working solutions is rapidly increasing across Egypt and the wider MENA region. The new centre is located at Signature, Park St. West in Sheikh Zayed City, as part of IWG’s continued expansion to meet the growing need for high-quality flexible office space in the region. This move follows the company’s record-breaking revenue performance in its 35-year history, highlighting its rapid network growth. As hybrid working becomes increasingly popular, IWG is offering a state-of-the-art facility designed to support businesses of all sizes, start-ups, students, and individuals. The new location will feature a variety of workspaces, including private offices, meeting rooms, co-working areas, and creative spaces, catering to the diverse needs of modern workers. The Signature location was developed in partnership with the building owners, who invested in IWG’s platform to maximize the return on their real estate assets. IWG’s flexible working solutions offer significant cost savings, with an average saving of £9,000 ($11,000) per employee, making it an attractive model for businesses. IWG also provides extensive support to partners, including technology platforms, design and fit-out assistance, and marketing capabilities. The growth of hybrid working is driving significant change in the commercial real estate market, with predictions that 30% of all commercial space will be flexible by 2030. As companies continue to adopt hybrid working for the long-term, the demand for flexible office space is expected to accelerate. In 2023 alone, IWG added over 800 new partner locations and serves 83% of the Fortune 500 companies. Marc Descrozaille, CEO for the Middle East & Africa at IWG, commented: “We are solidifying our presence in the MENA region, where the demand for high-quality flexible workspaces is soaring as hybrid working becomes the new norm.” Youssef Najeeb, IWG Country Manager for Egypt, added: “Egyptian companies are increasingly recognizing the benefits of the hybrid working model, improving employee satisfaction while also contributing to environmental sustainability.” Omar Shaheen, Managing Partner of Premier Offices, emphasized: “The opening of Signature is not just an expansion but a demonstration of our commitment to providing inspiring environments that help our clients succeed in an evolving workplace landscape.”None
Moody chickens? Playful bumblebees? Science decodes the rich inner lives of animals.3 TSX Stocks to Consider After Their Impressive Quarterly Results
Louisiana Tech earns 108-60 win over RustFans Think Nicole Kidman Is Lying About The Divorce Meme Origins — But I Have 4 Possible Theories
The Digital Shipyard Market: Transforming Maritime Operations Towards 2031 11-26-2024 09:52 PM CET | Advertising, Media Consulting, Marketing Research Press release from: Data Bridge Market Research (DBMR) Digital Shipyard Market The maritime industry is undergoing a revolutionary transformation, with the adoption of advanced technologies reshaping traditional shipyard operations. At the forefront of this transformation is the Digital Shipyard Market, an evolving sector that integrates Industry 4.0 principles into shipbuilding, maintenance, and repair. By leveraging tools such as the Internet of Things (IoT), Artificial Intelligence (AI), and Augmented Reality (AR), digital shipyards are driving efficiency, cost-effectiveness, and sustainability. This article delves into the dynamics of the digital shipyard market, exploring its trends, market size, share, growth trajectory, and the growing demand projected until 2031. Access Full 350 Pages PDF Report @ https://www.databridgemarketresearch.com/reports/global-digital-shipyard-market Digital shipyards embody the fusion of technology with traditional shipbuilding and maintenance practices. By digitizing processes such as design, construction, and lifecycle management, these shipyards enhance operational precision and reduce downtime. The core of this transformation lies in integrating data analytics, automated systems, and digital twins-a virtual replica of physical shipyard components used for simulation and predictive analysis. The need for modernized operations stems from the increasing complexity of maritime vessels and global competitiveness. Moreover, stringent environmental regulations and the demand for fuel-efficient ships necessitate innovation within shipyards. The digital shipyard concept is not just a response to these challenges but a proactive step towards building a sustainable maritime future. Key Trends in the Digital Shipyard Market Several key trends are driving the adoption of digital technologies in shipyards: Digital Twin Technology Digital twins are pivotal in enhancing the decision-making process by providing real-time insights into shipyard operations. This technology minimizes risks by simulating potential scenarios, thereby aiding in predictive maintenance and efficient resource allocation. IoT and Automation IoT-enabled sensors and devices facilitate seamless communication between shipyard equipment and systems. Automation of repetitive tasks, such as welding and material handling, further improves productivity and reduces errors. Augmented and Virtual Reality (AR/VR) AR and VR are transforming training modules and design reviews. Engineers can visualize ship designs and conduct virtual walkthroughs, significantly improving the accuracy of construction processes. AI-Powered Analytics Artificial Intelligence is being used to analyze large datasets, enabling better decision-making and resource management. AI also supports predictive maintenance by identifying potential issues before they escalate. Sustainability and Green Initiatives Digital shipyards are aligning with global efforts to reduce carbon emissions. By integrating energy-efficient practices and optimizing resource usage, they contribute to creating environmentally friendly maritime solutions. Market Size and Share of the Digital Shipyard Sector The global digital shipyard market size was valued at USD 1.17 billion in 2023 and is projected to reach USD 4.74 billion by 2031, with a CAGR of 19.10% during the forecast period of 2024 to 2031. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, import/export analysis, pricing analysis, production consumption analysis, and pestle analysis. Regionally, the market dynamics differ: North America leads due to robust technological advancements and strong defense budgets. Europe follows closely, driven by stringent environmental policies and the modernization of its maritime infrastructure. Asia-Pacific is emerging as a lucrative market, particularly with countries like China and South Korea investing heavily in smart shipyard initiatives to dominate global shipbuilding. In terms of market share, major players include shipbuilding giants and technology providers collaborating to deliver innovative digital solutions. Growth Drivers of the Digital Shipyard Market Several factors contribute to the growth of the digital shipyard market: Modernization of Existing Infrastructure Many traditional shipyards are investing in digital upgrades to remain competitive. This modernization helps improve productivity, reduces costs, and enhances worker safety. Demand for Advanced Vessels The growing demand for technologically advanced ships, including autonomous and smart vessels, is a major driver for the adoption of digital shipyard solutions. Government Initiatives and Investments Governments worldwide are funding projects aimed at upgrading maritime infrastructure and fostering innovation in shipyard operations. Rising Need for Operational Efficiency Digital shipyards address inefficiencies in traditional shipbuilding processes by streamlining operations and reducing lead times. Integration with Defense Sectors The naval defense sector increasingly relies on digital shipyards for building and maintaining sophisticated warships and submarines, ensuring operational readiness. Future Demand and Prospects Until 2031 The demand for digital shipyards is expected to surge significantly in the coming years, driven by technological advancements and global market needs. By 2031, the market is projected to witness the following developments: Increased Adoption of AI and Robotics: AI-powered robots will take over tasks requiring high precision, such as welding and inspection, enhancing productivity and quality. Expansion of Digital Twin Applications: From ship design to maintenance, digital twins will play an increasingly crucial role in lifecycle management. Focus on Cybersecurity: As shipyards digitize, the importance of securing sensitive data will lead to substantial investments in cybersecurity solutions. Collaborative Innovation: Partnerships between shipbuilders and tech companies will accelerate the development of cutting-edge digital shipyard solutions. Sustainability as a Core Value: The emphasis on reducing carbon footprints and adopting eco-friendly practices will remain central to the evolution of digital shipyards. Browse Trending Reports: https://aimarketresearch2024.blogspot.com/2024/11/cnc-controller-market-size-share-trends.html https://aimarketresearch2024.blogspot.com/2024/11/colored-gemstones-market-size-share.html https://aimarketresearch2024.blogspot.com/2024/11/consumer-electronics-market-size-share.html https://aimarketresearch2024.blogspot.com/2024/11/cricket-bowling-machine-market-size.html Conclusion The digital shipyard market represents a paradigm shift in the maritime industry, blending innovation with tradition to create efficient, sustainable, and cost-effective operations. As we approach 2031, the sector's growth trajectory is clear, fueled by technological advancements and the global push for smarter, greener solutions. For stakeholders in the maritime industry, investing in digital shipyard technologies is not just a choice but a necessity for staying competitive in an evolving market landscape. About Data Bridge Market Research: Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Contact Us: Data Bridge Market Research US: +1 614 591 3140 UK: +44 845 154 9652 APAC : +653 1251 975 Email: corporatesales@databridgemarketresearch.com" This release was published on openPR.It’s Michigan’s first 4-game win streak vs. Ohio State in decades
Trump team signs transition agreement with Biden White House after delaysRussia fired experimental ballistic missile at Ukraine, Putin says
Millions more Americans might get access to GLP-1 drugs
CORPUS CHRISTI, Texas (AP) — Garry Clark scored 15 points as Texas A&M-Corpus Christi beat Prairie View A&M 109-74 on Saturday night. Clark also contributed five rebounds for the Islanders (5-3). Dian Wright-Forde shot 5 of 6 from the field and 3 of 4 from the free-throw line to add 14 points. Jordan Roberts shot 4 of 6 from the field, including 2 for 4 from 3-point range, and went 4 for 5 from the line to finish with 14 points. The Panthers (1-6) were led in scoring by Tanahj Pettway, who finished with 21 points and six rebounds. Nick Anderson added 15 points and two steals for Prairie View A&M. Marcel Bryant had 14 points and 10 rebounds. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .Parainfluenza Virus Infection Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Clinical Trials | Ansun Biopharma, AlloVir, Ansun Biopharma 11-21-2024 08:51 PM CET | Health & Medicine Press release from: DelveIinsight Business Research (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Parainfluenza Virus Infection pipeline constitutes 5+ key companies continuously working towards developing 5+ Parainfluenza Virus Infection treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Parainfluenza Virus Infection Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Parainfluenza Virus Infection Market. The Parainfluenza Virus Infection Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Some of the key takeaways from the Parainfluenza Virus Infection Pipeline Report: https://www.delveinsight.com/sample-request/parainfluenza-virus-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr •Companies across the globe are diligently working toward developing novel Parainfluenza Virus Infection treatment therapies with a considerable amount of success over the years. •Parainfluenza Virus Infection companies working in the treatment market are Ansun Biopharma, AlloVir, Ansun Biopharma, and others, are developing therapies for the Parainfluenza Virus Infection treatment •Emerging Parainfluenza Virus Infection therapies in the different phases of clinical trials are- DAS181, ALVR106, Oplunofusp, and others are expected to have a significant impact on the Parainfluenza Virus Infection market in the coming years. Parainfluenza Virus Infection Overview Parainfluenza virus infection is a respiratory illness caused by human parainfluenza viruses (HPIVs), a group of viruses that primarily affect the respiratory tract. These infections are common, especially in children, and can cause a range of illnesses, from mild colds to severe conditions like croup, bronchitis, and pneumonia. HPIVs spread through respiratory droplets or contact with contaminated surfaces. Symptoms often include fever, cough, runny nose, and difficulty breathing. While most cases resolve without complications, severe infections may occur in immunocompromised individuals, the elderly, and young children. Treatment focuses on symptom relief, as there is no specific antiviral therapy for HPIV. Get a Free Sample PDF Report to know more about Parainfluenza Virus Infection Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/parainfluenza-virus-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Emerging Parainfluenza Virus Infection Drugs Under Different Phases of Clinical Development Include: •DAS181: Ansun Biopharma •ALVR106: AlloVir •Oplunofusp: Ansun Biopharma Parainfluenza Virus Infection Route of Administration Parainfluenza Virus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as •Oral •Parenteral •Intravenous •Subcutaneous •Topical Parainfluenza Virus Infection Molecule Type Parainfluenza Virus Infection Products have been categorized under various Molecule types, such as •Monoclonal Antibody •Peptides •Polymer •Small molecule •Gene therapy Parainfluenza Virus Infection Pipeline Therapeutics Assessment •Parainfluenza Virus Infection Assessment by Product Type •Parainfluenza Virus Infection By Stage and Product Type •Parainfluenza Virus Infection Assessment by Route of Administration •Parainfluenza Virus Infection By Stage and Route of Administration •Parainfluenza Virus Infection Assessment by Molecule Type •Parainfluenza Virus Infection by Stage and Molecule Type DelveInsight's Parainfluenza Virus Infection Report covers around 5+ products under different phases of clinical development like •Late-stage products (Phase III) •Mid-stage products (Phase II) •Early-stage product (Phase I) •Pre-clinical and Discovery stage candidates •Discontinued & Inactive candidates •Route of Administration Further Parainfluenza Virus Infection product details are provided in the report. Download the Parainfluenza Virus Infection pipeline report to learn more about the emerging Parainfluenza Virus Infection therapies at: https://www.delveinsight.com/sample-request/parainfluenza-virus-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key companies in the Parainfluenza Virus Infection Therapeutics Market include: Key companies developing therapies for Parainfluenza Virus Infection are - AlloVir, Ansun Biopharma, Moderna Therapeutics, and others. Parainfluenza Virus Infection Pipeline Analysis: The Parainfluenza Virus Infection pipeline report provides insights into •The report provides detailed insights about companies that are developing therapies for the treatment of Parainfluenza Virus Infection with aggregate therapies developed by each company for the same. •It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parainfluenza Virus Infection Treatment. •Parainfluenza Virus Infection key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. •Parainfluenza Virus Infection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. •Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Parainfluenza Virus Infection market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Parainfluenza Virus Infection drugs and therapies- https://www.delveinsight.com/sample-request/parainfluenza-virus-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Parainfluenza Virus Infection Pipeline Market Drivers •Rising Incidence, Advancements in Diagnostic Tools, Growing Awareness, Development of Vaccines, Supportive Healthcare Policies, are some of the important factors that are fueling the Parainfluenza Virus Infection Market. Parainfluenza Virus Infection Pipeline Market Barriers •However, Lack of Specific Treatments, High R&D Costs, Limited Awareness in Low-Income Regions, Seasonal Variability, Regulatory Challenges, and other factors are creating obstacles in the Parainfluenza Virus Infection Market growth. Scope of Parainfluenza Virus Infection Pipeline Drug Insight •Coverage: Global •Key Parainfluenza Virus Infection Companies: Ansun Biopharma, AlloVir, Ansun Biopharma, and others •Key Parainfluenza Virus Infection Therapies: DAS181, ALVR106, Oplunofusp, and others •Parainfluenza Virus Infection Therapeutic Assessment: Parainfluenza Virus Infection current marketed and Parainfluenza Virus Infection emerging therapies •Parainfluenza Virus Infection Market Dynamics: Parainfluenza Virus Infection market drivers and Parainfluenza Virus Infection market barriers Request for Sample PDF Report for Parainfluenza Virus Infection Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/parainfluenza-virus-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Table of Contents 1. Parainfluenza Virus Infection Report Introduction 2. Parainfluenza Virus Infection Executive Summary 3. Parainfluenza Virus Infection Overview 4. Parainfluenza Virus Infection- Analytical Perspective In-depth Commercial Assessment 5. Parainfluenza Virus Infection Pipeline Therapeutics 6. Parainfluenza Virus Infection Late Stage Products (Phase II/III) 7. Parainfluenza Virus Infection Mid Stage Products (Phase II) 8. Parainfluenza Virus Infection Early Stage Products (Phase I) 9. Parainfluenza Virus Infection Preclinical Stage Products 10. Parainfluenza Virus Infection Therapeutics Assessment 11. Parainfluenza Virus Infection Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Parainfluenza Virus Infection Key Companies 14. Parainfluenza Virus Infection Key Products 15. Parainfluenza Virus Infection Unmet Needs 16 . Parainfluenza Virus Infection Market Drivers and Barriers 17. Parainfluenza Virus Infection Future Perspectives and Conclusion 18. Parainfluenza Virus Infection Analyst Views 19. Appendix 20. About DelveInsight Latest Reports: •Sglt2 Inhibitors Market: https://www.delveinsight.com/report-store/sglt2-inhibitors-market •Electroencephelographs Pipeline Insight: https://www.delveinsight.com/report-store/epilepsy-pipeline-insight •Fabry Disease Market: https://www.delveinsight.com/report-store/fabry-disease-market •Dental Implants And Prosthesis Market: https://www.delveinsight.com/report-store/dental-implants-and-prosthesis-market •Peritoneal Dialysis Equipment Market: https://www.delveinsight.com/report-store/peritoneal-dialysis-equipment-market •Drug-eluting Stents Market Market: https://www.delveinsight.com/report-store/drug-eluting-stents-market •Sinusitis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-with-nasal-polyps-market Contact Us: Gaurav Bora gbora@delveinsight.com +14699457679 Healthcare Consulting https://www.delveinsight.com/consulting-services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. This release was published on openPR.None
For ‘A Complete Unknown,’ Arianne Phillips Had to Dress Over 4,000 People in Period CostumesRegarding selling luxury cars, brands like Ferrari RACE , Rolls-Royce and Maserati use strategies that are as extravagant as their vehicles. These automakers know how to make their cars irresistible – and sometimes even make their customers feel like they're getting a deal when doing the company's work for them. Take Ferrari, for instance. A prominent marketing expert, Rory Sutherland, pointed out how the brand has devised a smart way to shift delivery costs onto its customers while framing it as an exclusive experience. The company can deliver a Ferrari to your local dealership for free if you buy it. But for around £500 ($630), you can opt for a “factory tour” in Maranello, Italy, where you pick up your car and drive it home at your own cost. Don't Miss: Deloitte's fastest-growing software company partnered with Amazon, Walmart & Target announces the deadline to invest this year is 12/20. – Last Chance to get 4,000 of its pre-IPO shares for just $0.26/share! The global games market is projected to generate $272B by the end of the year — for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market. Customers willingly pay to collect their cars because the experience is marketed as a unique privilege. It looks like a brilliant psychological play that makes customers feel special while cutting Ferrari's costs. Meanwhile, according to Sutherland, Rolls-Royce and Maserati took a different approach to make their luxury cars seem like impulse buys. Instead of showcasing their vehicles at traditional car shows – where their high price tags stand out – they moved to yacht and private jet shows. The logic? If you've spent all day looking at multimillion-dollar yachts and jets, a $250,000 car suddenly feels like a much smaller expense – an impulse buy. See Also: It’s no wonder Jeff Bezos holds over $70 million in art — this alternative asset has outpaced the S&P 500 since 1995, delivering an average annual return of 11.4%. Here’s how everyday investors are getting started. Ferrari is also making bold moves into cryptocurrency payments . After successfully rolling out crypto payments in the U.S., the brand expanded the option to Europe in July. Partnering with BitPay, Ferrari now accepts Bitcoin, Ethereum and USD Coin for its cars, instantly converting the payments to traditional currency. According to the company’s representative, this was done in response to consumer demand and to suit the tastes of their affluent, tech-savvy audience. By the end of 2024, Ferrari plans to offer crypto payments globally where legally permitted. Ferrari isn't stopping there. The brand is gearing up to launch its first electric supercar in the fourth quarter of 2025. Ferrari ensures its EVs maintain the brand’s signature appeal with a new factory in Maranello dedicated to hybrid and electric vehicles and a state-of-the-art lithium battery research lab. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — you can become an investor for $0.80 per share today. CEO Benedetto Vigna is reinventing the sound of electric motors to preserve the classic sensory experience of driving a Ferrari. Ferrari is placing a big bet on strong consumer interest across age groups to compete with market leaders like Tesla. Even as Ferrari accelerates into the future, its financial performance remains strong. The automaker reported an 11% year-over-year sales growth in Q1 2024, bringing in $1.72 billion in revenue. Shipments held steady at 3,560 units and Ferrari is on track for fiscal 2024 net revenues exceeding €6.4 billion. Whether paying to pick up your car, splurging on a $250,000 vehicle after looking at luxury yachts or buying a Ferrari with Bitcoin, one thing stands out: luxury car brands know how to keep people coming back. They use smart strategies, cool technology and new financial trends to stay ahead in the world of high-end cars. Read Next: Inspired by Uber and Airbnb – Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets – The deadline to invest and receive your shares this year is 12/20. Join 30,000+ shareholders and invest at $0.26/share today. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it ? © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Baldur’s Gate 3 is getting its biggest update yet with 12 new subclasses
Life expectancy in the U.S. varies by more than 20 years depending on an individual's race and ethnicity and where they live. These widespread and persistent life expectancy disparities have divided the country into "ten Americas," according to new research examining inequities in US life expectancy between 2000 and 2021, published in The Lancet . "The extent and magnitude of health disparities in American society are truly alarming in a country with the wealth and resources of the U.S.," said senior author Professor Christopher JL Murray, Director of the Institute for Health Metrics and Evaluation (IHME), University of Washington, Seattle, U.S. "These disparities reflect the unequal and unjust distribution of resources and opportunities that have profound consequences on well-being and longevity, especially in marginalized populations. "Policymakers must take collective action to invest in equitable health care, education, and employment opportunities and challenge the systemic barriers that create and perpetuate these inequities so that all Americans can live long, healthy lives regardless of where they live and their race, ethnicity, or income." The findings come nearly two decades after the landmark "Eight Americas" study, which examined the interacting drivers of health inequities in the U.S. by dividing the US population into eight groups based on geography, race, urbanicity, income per capita, and homicide rate . In this new study, researchers update and expand the original Eight Americas study, dividing the US population into ten mutually exclusive populations, or "Americas," based on race and ethnicity and other variables such as geographic location, metropolitan status, income, and residential segregation. Analyzing death records from the National Vital Statistics System and population estimates from the National Center for Health Statistics, researchers estimated trends in life expectancy at birth—an important indicator of a population's health—from 2000 to 2021 for each of the ten Americas by year, sex, and age group. Stark differences in life expectancy have widened over two decades Despite efforts to reduce health inequalities, the life expectancy gap between the Americas was 12.6 years in 2000 and grew even larger during the 2000s and 2010s (reaching 13.9 years in 2010 and 15.6 years by 2019), and accelerated to 20.4 years after the first two years of the COVID-19 pandemic. In 2000, Black Americans living in rural, low-income counties in the South (America 9) and Black Americans living in highly-segregated cities (America 7) had the lowest life expectancy (around 70.5 years for both populations), while Asian Americans (America 1) had the highest life expectancy, living on average 83.1 years. Between 2000 and 2010, life expectancy increased for every America except for American Indian and Alaska Native (AIAN) people living in the West (America 10), who had the shortest lifespan in 2010 after a one-year drop in life expectancy from 72.3 years in 2000 to 71.2 years in 2010. During this time, the three Black Americas (6, 7, and 9) showed some of the largest gains in life expectancy, increasing by as much as 3.7 years, with Black Americans living in other counties (America 6) exceeding the life expectancy of white Americans living in low-income counties in Appalachia and the lower Mississippi Valley (America 8) from 2010 onward, except in 2020. "The gap between life expectancy at birth for Black and white Americans may never have been narrower than it was in the mid-2010s," said co-author Thomas Bollyky from the Council of Foreign Relations, Washington DC, U.S. "It's likely that long-term improvements in education available to Black children and young adults in recent decades, as well as reductions in homicide rates and deaths from HIV/AIDS—causes of death that have disproportionately impacted Black Americans—may have contributed to these noteworthy gains for Black Americans." However, in the following decade (2010–2019), improvements in life expectancy at birth for the three Black Americas (Americas 6, 7, and 9)—as well as all the other Americas—largely stalled. This pattern may be explained by an increase in drug overdose deaths and homicides as well as a slowdown in reductions in cardiovascular disease deaths, likely related to increases in obesity. Widening racial life expectancy gap during the first two years of the COVID-19 pandemic The COVID-19 pandemic precipitated a staggering drop in life expectancy for all the Americas and substantially widened racial disparities in lifespan. For example, while Black Americans living in highly segregated cities (America 7) and Black Americans living in rural, low-income counties in the South (America 9) were expected to live an average 74.9 years and 72.5 years, respectively, in 2019, this fell by approximately 4.0 years in 2020. For white (the majority), Asian, and AIAN people living in other counties (America 3), the corresponding decline was only 1.4 years—from 79.3 years in 2019 to 77.9 years in 2020. Marginalized groups already had lower life expectancy, and the pandemic further increased the gap. By 2021, Asian Americans (America 1) still had the longest life expectancy at birth, living on average 84 years—a striking 20.4 years longer than AIAN people living in the West (America 10), who had the lowest life expectancy at 63.6 years. Alarming health crisis for American Indian and Alaska Native people in the West AIAN people living in the West (America 10) were the only group to experience a drop in their life expectancy between 2000 and 2010 and again between 2010 and 2019—falling from the already relatively low 72.3 years in 2000 to 70.2 years in 2019. COVID-19 set them even further behind the other Americas, with a 6.6-year drop in life expectancy between 2019 and 2021. These findings suggest that AIAN people are living much shorter lives than any other population due to systemic barriers that have perpetuated social, economic, and health inequities. For example, inadequate health care access and chronic underfunding of Indigenous health services, together with high rates of unemployment and low rates of educational attainment, and the legacy of systemic discrimination, are factors that likely contribute to AIAN people dying at higher rates from highly preventable causes like chronic diseases, smoking, and drug overdose, as well as COVID-19. What is driving these disparities in life expectancy? The findings suggest that differences in educational attainment and income likely explain some of the disparities in life expectancy. For example, Black Americans living in rural, low-income counties in the South (America 9) and AIAN individuals living in the West (America 10) had the lowest income per capita and percentage graduating college as well as the lowest life expectancy in most years between 2000 and 2021. However, the authors note some unexpected disparities, which indicate that other factors beyond income and education can contribute to differences in longevity. For example, white (the majority), Asian, and AIAN people living in other counties (America 3) had the highest income in most years, as well as the highest proportion graduating high school and the second highest percentage of college graduates but was ranked only fourth or fifth in life expectancy prior to 2020. According to co-author Professor Ali Mokdad from IHME, "More research is needed to fully understand why life expectancy is worse for some Americans, so we can better tackle the root causes of poor health for the most disadvantaged. "America's life expectancy gap is unlikely to diminish until a comprehensive, coordinated approach that includes preventive measures and public health initiatives that transcend political divides and fosters collaboration and accountability between state, local, and national entities is developed. "Only then can we hope to create a more equitable and healthier society for all the Americas—and all Americans." The authors point out that the grouping of the US population based on county, race and ethnicity is not the only division that could be used to understand the large inequalities in US life expectancy, and different choices of factors would lead to different results. The authors also note some important study limitations, including that there is a well-known misreporting of race and ethnicity on death certificates, and although they corrected for this misclassification, it increased the uncertainty around the estimates. They also note that data on income per capita and educational attainment from the America Community Survey and 2000 decennial census used different racial and ethnic groups compared to those used in the analysis, which could lead to a mismatch in the estimates of income and educational attainment for three groups (combined AIAN, Asian and NHPI, and Black) and the corresponding Americas. Additionally, while this analysis shows large disparities in life expectancy between the ten Americas, the authors note that there will also be large disparities within these Americas. For example, research shows considerable differences in life expectancy among counties, even for the same racial and ethnic group. Finally, while the ten Americas is defined based on data from a single point in time (primarily 2020), some of the characteristics these definitions are based on are time-varying (eg, income per capita), so it is likely that some county and race and ethnicity combinations would be included in different Americas if data from a different year were used to define the Americas. Writing in a linked Comment, Professor Steven H Woolf from the Virginia Commonwealth University School of Medicine, U.S. (who was not involved in the study), says that the study confirms the continued existence of different Americas in the U.S., adding that, "The study also underscores the value of investigating intersectionality. Disaggregated data can inform policy decisions about which geographic regions and populations to prioritize in efforts to reduce disparities in life expectancy. "Understanding the root causes of disparate mortality rates and meaningful efforts to address the social and environmental determinants of health are essential to close the gap." More information: Ten Americas: a systematic analysis of life expectancy disparities in the USA, The Lancet (2024). DOI: 10.1016/S0140-6736(24)01495-8FEDPAC Sponsors Lakapi Samoa Oceania 7s Campaign